Anavex moving on MOA with patent and hires?
Anavex recently posted on Indeed, for a "Medical Monitor" position which seems to be the primary contact between Anavex and test sites.
Anavex today PRed, for its patent application number 16/717921 expanding coverage for A2-73 and related SR1 agonist drug candidates, for treating a range neurodevelopmental disorders. Indeed, for patent application 20200246303 (referencing application 16/717921), claim 2 states "...the neurodevelopmental disorder is selected from the group consisting of cerebral palsy, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, Smith-Magenis syndrome, Rett syndrome, and autism spectrum disorder."
Is Ana moving towards an MOA (mechanism of action) approach? Will this approach require many small data collecting phase3 trials to justify MOA for each disorder? Is this the reason for the new hire, to manage these trials? Will we see new trials start for these disorders? No connection?
Market Data 
Markets 
AI
